Literature DB >> 28721490

FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.

Joshua I Warrick1,2, Matthew Kaag3, Jay D Raman3, Wilson Chan4, Truc Tran4, Sudhir Kunchala4, Lauren Shuman4, David DeGraff4,3,5, Guoli Chen6.   

Abstract

Invasive bladder cancer is diverse, and includes several named histomorphologies that differ from conventional urothelial carcinoma, termed "histologic variants." By transcriptional analysis, bladder cancers can be divided into luminal and basal subtypes. In this paper, we study associations between markers of transcriptional subtypes and variant histology in a retrospective cohort of 309 cystectomy specimens. Histology slides were methodically reviewed for all cases, and variant histology was documented. Immunohistochemistry for FOXA1 (luminal marker) and CK14 (basal maker) was performed on histologic variants and their associated conventional urothelial carcinomas. Invasive carcinoma was present in 270 of the cystectomy specimens, 35% of which contained a histologic variant. Squamous carcinomas expressed higher CK14 levels than micropapillary, nested, and plasmacytoid carcinomas (p < 0.001, Kruskal-Wallis), keeping with the basal character of squamous carcinoma. Likewise, squamous carcinomas expressed lower FOXA1 levels than micropapillary, nested, and plasmacytoid carcinomas (p < 0.001, Kruskal-Wallis), keeping with the luminal character of micropapillary carcinoma, and suggesting that nested and plasmacytoid cancers have luminal character. FOXA1 was expressed at lower levels in conventional urothelial carcinoma associated with squamous carcinoma than conventional urothelial carcinoma associated with micropapillary carcinoma (p = 0.0072, Wilcoxon rank sum). CK14 expression did not differ between conventional urothelial carcinomas associated with squamous versus micropapillary carcinoma (p = 0.89, Wilcoxon rank sum). Instead, CK14 expression was higher in squamous carcinoma than conventional urothelial carcinoma present in the same bladder (p = 0.014, Wilcoxon rank sum, paired). Overall, the findings show that squamous and micropapillary cancers have different expression patterns of CK14 and FOXA1 and suggest that they arise from distinct precursors.

Entities:  

Keywords:  Basal marker; Histological variant; Luminal marker; Urothelial carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28721490     DOI: 10.1007/s00428-017-2190-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Authors:  Massimiliano Spaliviero; Guido Dalbagni; Bernard H Bochner; Bing Ying Poon; Hongying Huang; Hikmat A Al-Ahmadie; Timothy F Donahue; Jennifer M Taylor; Joshua J Meeks; Daniel D Sjoberg; S Machele Donat; Victor E Reuter; Harry W Herr
Journal:  J Urol       Date:  2014-03-03       Impact factor: 7.450

2.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas.

Authors:  P Harnden; J Southgate
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

4.  Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists.

Authors:  Ankur R Sangoi; Andrew H Beck; Mahul B Amin; Liang Cheng; Jonathan I Epstein; Donna E Hansel; Kenneth A Iczkowski; Antonio Lopez-Beltran; Esther Oliva; Gladell P Paner; Victor E Reuter; Jae Y Ro; Rajal B Shah; Steven S Shen; Pheroze Tamboli; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

Review 5.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

6.  The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

Authors:  Ashish M Kamat; Jason R Gee; Colin P N Dinney; H Barton Grossman; David A Swanson; Randall E Millikan; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

7.  Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.

Authors:  Jay D Raman; Joshua I Warrick; Carla Caruso; Zhaohai Yang; Lauren Shuman; Richard D Bruggeman; Shahrokh Shariat; Jose A Karam; Christopher Wood; Alon Z Weizer; Mesut Remzi; Andrea Haitel; Karim Bensalah; Nathalie Rioux-Leclerq; Christian Bolenz; Marco Roscigno; Laura-Maria Krabbe; Payal Kapur; Yair Lotan; Vitaly Margulis; David J DeGraff
Journal:  Urology       Date:  2016-05-20       Impact factor: 2.649

8.  Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

Authors:  Ashish M Kamat; Colin P N Dinney; Jason R Gee; H Barton Grossman; Arlene O Siefker-Radtke; Pheroze Tamboli; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

9.  Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

Authors:  David J DeGraff; Peter E Clark; Justin M Cates; Hironobu Yamashita; Victoria L Robinson; Xiuping Yu; Mark E Smolkin; Sam S Chang; Michael S Cookson; Mary K Herrick; Shahrokh F Shariat; Gary D Steinberg; Henry F Frierson; Xue-Ru Wu; Dan Theodorescu; Robert J Matusik
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

10.  Micropapillary Bladder Cancer: Insights from the National Cancer Database.

Authors:  Wilson Sui; Justin T Matulay; Maxwell B James; Ifeanyi C Onyeji; Marissa C Theofanides; Arindam RoyChoudhury; G Joel DeCastro; Sven Wenske
Journal:  Bladder Cancer       Date:  2016-10-27
View more
  14 in total

Review 1.  Genomic Subtyping in Bladder Cancer.

Authors:  Tuomas Jalanko; Joep J de Jong; Ewan A Gibb; Roland Seiler; Peter C Black
Journal:  Curr Urol Rep       Date:  2020-03-13       Impact factor: 3.092

Review 2.  Molecular Subtypes of Bladder Cancer.

Authors:  David J McConkey; Woonyoung Choi
Journal:  Curr Oncol Rep       Date:  2018-08-20       Impact factor: 5.075

3.  Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.

Authors:  Lisa Han; Alexander J Gallan; Gary D Steinberg; Randy F Sweis; Gladell P Paner
Journal:  Hum Pathol       Date:  2020-09-26       Impact factor: 3.466

Review 4.  Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.

Authors:  Hikmat Al-Ahmadie; Gopa Iyer
Journal:  Surg Pathol Clin       Date:  2018-10-17

Review 5.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

6.  Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis.

Authors:  Di Jin; Kun Jin; Shi Qiu; Xianghong Zhou; Qiming Yuan; Lu Yang; Qiang Wei
Journal:  Cancer Med       Date:  2020-06-11       Impact factor: 4.452

7.  FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.

Authors:  Danijel Sikic; Markus Eckstein; Ralph M Wirtz; Jonas Jarczyk; Thomas S Worst; Stefan Porubsky; Bastian Keck; Frank Kunath; Veronika Weyerer; Johannes Breyer; Wolfgang Otto; Sebastien Rinaldetti; Christian Bolenz; Arndt Hartmann; Bernd Wullich; Philipp Erben
Journal:  J Clin Med       Date:  2020-04-02       Impact factor: 4.241

8.  Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.

Authors:  Aaron A Mehus; Nicholas Bergum; Peter Knutson; Swojani Shrestha; Xu Dong Zhou; Scott H Garrett; Donald A Sens; Mary Ann Sens; Seema Somji
Journal:  PLoS One       Date:  2020-08-21       Impact factor: 3.240

9.  Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.

Authors:  Juliana Naves Ravanini; Aline Kawassaki Assato; Alda Wakamatsu; Venâncio Avancini Ferreira Alves
Journal:  Clinics (Sao Paulo)       Date:  2021-04-26       Impact factor: 2.365

10.  NFkB hyperactivation causes invasion of esophageal squamous cell carcinoma with EGFR overexpression and p120-catenin down-regulation.

Authors:  Heather L Lehman; Michal Kidacki; Joshua I Warrick; Douglas B Stairs
Journal:  Oncotarget       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.